PeppiLibrary

Metabolic

Semaglutide peptide reference

FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management.

Last reviewed May 6, 2026 FDA-approved FDA approved
Peppi reviewing Semaglutide notes
Default dose label250 mcg
Preferred routeSubQ
Frequency label1× weekly
Storage window28 days mixed

Evidence snapshot

FDA-approved

Evidence maturityFDA approved
FDA-approved with extensive Phase 3 trials (SUSTAIN, STEP programs)

Prescription medication

Route map

How records are usually labeled

1 SubQ
2 Oral

Rotate weekly between abdomen, thigh and upper arm to minimise lipohypertrophy.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; do not freeze (degrades active drug).
After mixPen in use: room temperature ≤30 °C up to 56 days OR refrigerated. Compounded vials: refrigerate, use within 28 days.
Use-by cue28 days after mixing
Mixed vial window28 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 2 mg vial
Dose 250 mcg
Route SubQ
Review 28d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Semaglutide. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It mimics endogenous GLP-1 with structural modifications (Aib-2 substitution and a fatty acid chain) that resist DPP-4 degradation and enable albumin binding for a ~7-day half-life. FDA-approved as Ozempic (T2D, 2017), Wegovy (chronic weight management, 2021) and Rybelsus (oral T2D, 2019).

Also known as: Ozempic, Wegovy, Rybelsus.

Type 2 diabetes glycemic controlChronic weight management (BMI ≥30 or ≥27 with comorbidity)Cardiovascular risk reduction in T2D

Mechanism and timing snapshot

Activates GLP-1 receptors on pancreatic β-cells (glucose-dependent insulin secretion), in the gut (delayed gastric emptying) and in the brain (appetite suppression via hypothalamic centres).

Onset labelNot listed
Catalog onset field, when available.
Half-life label168 hr
~7 days plasma half-life; steady-state reached in ~4–5 weeks
Duration label168 hr
Catalog duration field, when available.
subQ ~89%
oral ~0.4–1% (Rybelsus formulation includes absorption enhancer SNAC)

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose250 mcg
Catalog dose range250 mcg - 2.4 mg
Default routeSubQ
Frequency label1× weekly
Best time labelSame day each week, any time of day; with or without food.
Food noteNone for injectable; oral Rybelsus must be taken on empty stomach with ≤120 mL water and 30 min fast after.

Catalog protocol note

Titration: 0.25 mg weekly × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg × 4 weeks → up to 2.4 mg weekly (Wegovy max).

Routes and site notes

Available route labelsSubQ, Oral
Preferred route labelSubQ
Common site labelsAbdomen, Thigh, Upper arm
Site rotation noteRotate weekly between abdomen, thigh and upper arm to minimise lipohypertrophy.

Chemistry

SequenceModified GLP-1(7-37) with Aib at position 2 and C18 fatty diacid at K26
Amino acids31
Molecular formulaC187H291N45O59
Molecular weight4113.6 Da

Vial, reconstitution, and storage

Supply formPre-filled multi-dose pen (commercial) OR lyophilized powder (compounded)
Typical vial size2 mg
DiluentBacteriostatic water (compounded only)
Diluent volume2 mL
Concentration noteCompounded 2 mg in 2 mL → 0.25 mL = 250 mcg starting dose. Commercial pens are pre-dosed.
Before reconstitutionRefrigerate 2–8 °C; do not freeze (degrades active drug).
After reconstitutionPen in use: room temperature ≤30 °C up to 56 days OR refrigerated. Compounded vials: refrigerate, use within 28 days.
Reconstituted shelf life28 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Nausea (30–50%, dose-dependent)
  • Constipation or diarrhea
  • Headache
  • Fatigue
  • Decreased appetite
  • Pancreatitis
  • Gallbladder issues
  • Diabetic retinopathy progression (T2D)
  • Acute kidney injury from dehydration

Contraindications and warnings

  • Personal/family history of medullary thyroid carcinoma
  • MEN 2 syndrome
  • Pregnancy
  • Pancreatitis history (caution)
  • FDA boxed warning for thyroid C-cell tumours (rodent data)
  • Discontinue if pancreatitis suspected

Other considerations

  • Slow titration is essential — escalating too fast causes severe nausea.
  • Maintain hydration; constipation is common.
  • GI symptoms typically resolve over 1–2 weeks at each new dose level.

Evidence and regulatory context

Evidence levelFDA-approved with extensive Phase 3 trials (SUSTAIN, STEP programs)
FDA approvedYes
Regulatory statusPrescription medication
Prescription requiredYes
Approved countriesUS, EU, UK, Canada, Japan, and many others

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteOther GLP-1 agonists, DPP-4 inhibitors (redundant mechanism)
Typical cycle labelongoing
Typical break labelNot typically cycled
Cycle guidanceUsed continuously; weight regain often follows discontinuation. Discuss tapering vs maintenance with a clinician.

Tracking tips

  • Pick a consistent day of the week — set a recurring reminder.
  • Stay aggressively hydrated and prioritise fibre to manage constipation.
  • Don't skip titration steps to chase faster results — GI side effects compound.
  • Discuss with a clinician — this is a regulated medication, not a research peptide.

References

Track it in Peppi

Keep Semaglutide records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Semaglutide?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Semaglutide?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Semaglutide records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026